This preprint reports a comprehensive, cell-type–resolved genetic regulatory atlas of human synovium and infrapatellar fat pad (IPFP) across the osteoarthritis (OA) spectrum. The authors aimed to integrate germline variation with transcriptomic and chromatin data to identify cis-regulatory effects, prioritize molecular targets that colocalize with OA genome-wide association study (GWAS) signals, and nominate tissue- and cell-type-specific mechanisms that may drive joint pathology beyond cartilage.
The study combined multiple data modalities from donor knee tissues spanning joint-disease-free to severe OA. Whole-genome sequencing and bulk transcriptomics were obtained for synovium (n=138 donors) and IPFP (n=70 donors). Single-nucleus multiomics profiling was performed, yielding 31,472 nuclei from synovium and 33,621 nuclei from IPFP. These datasets were integrated to map cis-regulatory relationships at cell-type resolution across the two joint tissues.
Using the combined genomic and transcriptomic resources, the investigators performed integrated cis-eQTL mapping separately in synovium and IPFP. They identified 970 eGenes in synovium and 487 eGenes in IPFP. The overlap between tissues was minimal, indicating that many cis-regulatory effects are tissue-specific even within anatomically adjacent joint compartments. The mapping therefore provides distinct regulatory catalogs for synovium and IPFP rather than a shared joint regulatory program.
The authors evaluated colocalization between eQTLs and published OA GWAS signals. Colocalization patterns were largely tissue-specific and in some cases differed between the same nominal cell type across synovium and IPFP. These results underscore that candidate causal mechanisms for OA loci may operate in different joint tissues and cell types, with important consequences for functional follow-up and therapeutic targeting.
The study applied a rare-variant analysis approach using Promoter AI to search for promoter variants affecting gene expression. This analysis nominated promoter variants predicted to reduce expression of VEGFA in both synovium and IPFP. The report describes these promoter variants as rare regulatory events with potential shared effects across the two tissues.
Single-nucleus multiomic data were used to nominate cell-type–specific regulatory elements. The authors identified an adipocyte-specific enhancer linked to expression of ABCA9 in IPFP. This observation highlights how single-nucleus chromatin and transcriptome integration can assign enhancers to target genes and cell types within joint adipose tissue.
By combining fine-mapping of genetic signals with chromatin accessibility data, the investigators prioritized RBM6, an RNA-binding protein, at an OA-associated locus. The OA risk allele at this locus was associated with increased inflammatory cytokine expression in synovial macrophages. This link suggests a mechanism by which a regulatory allele modifies macrophage inflammatory responses within the synovium.
Collectively, these results support a model in which OA is driven by distinct regulatory programs across multiple joint tissues rather than being solely a cartilage disease. The tissue- and cell-type-specific catalogs of eGenes, promoters, and enhancers provide prioritized candidates for functional validation and may refine the interpretation of OA GWAS loci. The authors emphasize that mechanistic effects at the same genetic locus can differ between synovium and IPFP, informing the tissue context needed for downstream experiments.
The work is reported as a preprint and has not undergone peer review; the authors caution that findings should not be used to guide clinical practice. Ethical approval was obtained from The Scripps Research Institute Human Subjects Committee (protocol 20-7636), and the authors state that participant consent and relevant reporting guidelines were followed. All data produced in the study are available upon reasonable request to the authors. Funding sources declared include the Japan Society for the Promotion of Science, the Japan Agency for Medical Research and Development, and the US National Institutes of Health.